Deutsche Bank Maintains Buy Rating on Akorn

According to Deutsche Bank, Akorn AKRX Buy rating is maintained. Deutsche Bank said that ViroPharma received an SNDA approval for its oral antiinfective Vancocin (vancomycin, approx $300M 2011 sales) - which has been the target of generic filers since 2007 (Akorn was an early filer). “According to ViroPharma, Vancocin's updated label is predicated on new clinical safety and efficacy data on the treatment of circulating strains of C. difficile the company purchased from Sanofi (GENZ).” Akorn closed yesterday at $10.70.